 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 04/18/2007 | | | | Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH
topic: R&D: BPH (enlarged prostate) Treatments
April 18, 2007: Nymox announced today completion of a new 42 month follow-up study of NX-1207 for benign prostatic
hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the
Company’s two Phase 1-2 studies initiated in 2003. Individuals in the study were assessed for
symptomatic improvement, treatment outcomes, and durability of efficacy. Patients in the study were assessed 3 1/2 years after NX-1207 treatment. The Company expects to conclude analysis of the
data in the next 1-2 weeks and will be reporting the results once they are completed.
|
| 03/19/2007 | | | | Nymox Announces Positive Results from Newly Completed Long-Term Study of NX-1207 for Benign Prostatic Hyperplasia
topic: R&D: BPH (enlarged prostate) Treatments
March 19, 2007: Nymox today announced positive results from its newly completed long-term outcome study of
NX-1207 for benign prostatic hyperplasia (BPH). The study, involving 26 clinical trial sites across the U.S.
and 116 unselected subjects, assessed symptom scores and treatment outcome 8-19 months after NX-1207 treatment. Overall, without further NX-1207 treatment, patients initially treated with
NX-1207 showed a total pooled mean improvement of 7.4 points in the primary outcome
endpoint of AUA Symptom Score values, which reached statistical significance when compared
with the placebo control. In terms of treatment outcomes, patients treated
with NX-1207 had statistically significantly more favorable outcomes compared to placebo. |
| 03/15/2007 | | | | Nymox Reports 2006 Financial Results
topic: Financial
March 15, 2007: Nymox Pharmaceutical Corporation announced today its financial results for the year ended December 31, 2006. |
| 02/28/2007 | | | | Nymox Reports Completion of New Long-term Study of NX-1207 for BPH
topic: R&D: BPH (enlarged prostate) Treatments
February 28, 2007: Nymox announced today completion of a new long-term follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). |
| 01/31/2007 | | | | Nymox Reports Update on Prostate Drug Licensing Negotiations
topic: Financial
January 31, 2007: Nymox announced today that the Company’s NX-1207 drug for the treatment of benign prostatic hyperplasia (BPH) has attracted serious expressions of interest from a number of major pharmaceutical companies wishing to license the drug for sale in global markets. |
| 01/25/2007 | | | | Journal of Clinical Laboratory Analysis Publishes Positive New Data Bolstering Nymox’s AlzheimAlert™ Urine Test for Alzheimer’s Disease
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
January 25, 2007: Nymox is pleased to announce the publication of a new peer-reviewed report in the most recent issue of the Journal of Clinical Laboratory Analysis providing further positive data on the accuracy and utility of the Company's urinary AlzheimAlert™ test. |
| 12/13/2006 | | | | Nymox Protein Biomarker for Alzheimer's is Years Ahead of Competition
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
December 13, 2006: Nymox's AlzheimAlert™ test is literally years ahead of the competition, according to Brian Doyle, Nymox's Senior Manager for Worldwide Sales and Marketing. The urine-based test, which measures levels of a protein-based biomarker for Alzheimer’s disease, is currently available to physicians in major markets, including Europe and the United States. |
| 12/12/2006 | | | | Nymox NXC-4720 Reduces E. Coli Contamination By 99%
topic: R&D: E coli and Other Antibacterial Treatments
December 12, 2006: Nymox is developing NXC-4720, the Company’s innovative new product targeting E. coli O157:H7 food poisoning at its source: the contamination of food products. Studies have shown that NXC-4720 is capable of reducing the level of E. coli O157:H7 contamination by over 99%. |
| 11/29/2006 | | | | Nymox Announces $13 Million Equity Financing
topic: Financial
November 29, 2006: Nymox announced today that the Company has secured new commitment for $13 million in private equity financing. The private placement of common stock is with institutional investors who have participated in previous successful financings for the company, and is priced at a 3% discount to the market price. There are no warrants with the placement and no restrictions on other corporate financing. |
| 11/22/2006 | | | | Newly Published Editorial in Expert Opinion on Investigational Drugs Says Statins May Be Good for Alzheimer's Disease
topic: Statins and Alzheimer's Disease
November 22, 2006: A newly published editorial in Expert Opinion on Investigational Drugs has concluded that statins, the widely used cholesterol drugs, “probably strike at the heart of the sporadic Alzheimer’s disease-inducing mechanism.” Nymox holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD, including for patients at risk for AD because of vascular-related risk factors or disease. |
|